

TOGETHER







| TOGETHER |

to cure cancer in the 21st century

 $0 0 0 \bullet 0$

As France and Europe's leading cancer centre and the world's third largest*, **Gustave Roussy cares for adults** and children with all types of cancer, rare or common, at all stages of the disease.



The Institute's medical and research teams work hard every day to carry out this mission with humanity and expertise. Combining prevention, care, research, and education, Gustave Roussy is rooted in continuous innovation to benefit patients.

TOGETHER

0 0 0 • 0

100, 000 outpatient stays 50,000

patients seen in consultation and/or hospitalisation including

13,000 new patients

16,200 inpatient stays in full hospitalisation

3,200 employees (FTE)

480 M €
of global
budget

10 joint research units

472 _a

nd 135

96 families of patent

1,150 caregivers

• Villejuif site :

398 beds and 106 day hospital places

• Chevilly-Larue site:

74 beds and 29 day hospital places

620 doctors

164
international
publications in journals
with impact factor > 30
[excluding conferences]

1,150 research

10 doctor-researchers in the Highly cited researchers list in 2022

(out of 12 in France in oncology)



3,300 students trained

—and—

11,000 registered on the teaching platform

36 research teams



40%

of patients followed are included in clinical studies



a state-of-the-art medicine

00000

Gustave Roussy's teams innovate to offer high-quality, less invasive, earlier and more personalised care, with one objective: to optimise care pathways, to cure more and offer a better life after cancer. Gustave Roussy combines innovation and humanity, taking into account not only care but also physical, psychological and social quality of life.

The Institute is equipped with high-tech infrastructures: operating rooms, intensive care units, robotic surgery, cutting-edge outpatient surgery and interventional radiology platforms, completely revamped radiotherapy and imaging platforms, three chemotherapy preparation robots, a genomics platform...

With its Interception programme, Gustave Roussy offers personalised prevention for people identified as being at increased risk of cancer, in order to intercept the disease at an early stage.

300,000 medical consultations

14,000 day case procedures

3,700 patients treated with radiotherapy

2,600
patients treated
by interventional
radiology

215
patients treated
with tomotherapy

17,000 inpatients

3,500 patients seen in pediatric consultations, including

475 new patients

4,400 patients treated surgically

5,800 patients treated with chemotherapy



WORKING TOGETHER

for therapeutic progress

 $0 0 0 \bullet 0$

Gustave Roussy brings together the best players in fundamental, clinical and exploratory research. Close collaboration between researchers and doctors means quicker access to the most advanced therapeutic innovations for patients.



With the launch of the Paris-Saclay Cancer Cluster, Gustave Roussy is part of an ecosystem that fosters excellence in multidisciplinary and collaborative research. The aim is to accelerate the provision of innovative treatments and improve cancer care.

The Prism programme awarded as Institut hospitalo-universitaire

Supported by a multi-partner consortium, Prism, the "national centre for precision medicine in the fight against cancer", becomes a university hospital institute.

64 researches promoted by **Gustave Roussy** open to inclusion



453 publications in journals with impact factor greater than 10

(excluding congresses)

10

Gustave Roussy experts among the most cited in the world in the Clarivate / Web of science list

437 patients included in early trials (phase I and I/II)

584

clinical trials open for inclusion.

87% of those are therapeutic trials




59% are promoted by an industry

SPREADING EXPERTISE TOGETHER

to perform

Education and training are deeply rooted in Gustave Roussy's culture, committed to transfer its experience to all professionals involved in cancer care: doctors, researchers, caregivers and students.

Through its teaching division, Gustave Roussy supports those involved in the fight against cancer and anticipates future revolutions in oncology. Attached to the Paris-Saclay University, Gustave Roussy Education trains professionals for tomorrow's oncology professions. Gustave Roussy is also home to the $\it École doctorale de cancérologie, the only single-discipline doctoral school in oncology in France.$



WORKING TOGETHER

to accelerate success

00000

Individuals, associations, companies and major donors: the generosity of all embodies the hope of curing cancer.



Gustave Roussy is a private, non-profit healthcare establishment with collective interest, authorized to receive donations, beguests and gifts, like its Foundation. They both have been awarded the "Don en confiance" label by the Comité de la Charte, to attest the transparency of fundraising procedures and the sound management of donations received.

16.8 M€ allocated for fundamental clinical research projects

39 M€

in donations and bequests collected by Gustave Roussy and its Foundation in 2022 including

> raised through bequests and gifts

9.9 M€

9 M€ granted to strategic investments





A rigorous management:

14% of fundraising costs

DOCTORS, CAREGIVERS, RESEARCHERS, STUDENTS, DONORS... THE UNION OF ALL ENERGIES AND TALENTS IS OUR STRENGTH. TOGETHER WE CAN CURE ADULT AND CHILDHOOD CANCER IN THE 21ST CENTURY



